Status:
RECRUITING
Deep Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder
Lead Sponsor:
St. Joseph's Healthcare Hamilton
Conditions:
Cannabis Use Disorder
Eligibility:
All Genders
25-65 years
Phase:
NA
Brief Summary
There is a credible basis for lateral prefrontal cortex and insula deep repetitive transcranial magnetic stimulation (dTMS) stimulation as a treatment for cannabis use disorder (CUD), but no studies t...
Detailed Description
Deep repetitive transcranial magnetic stimulation (dTMS) is a technique that stimulates areas of the brain using magnetic pulses and is an approved treatment for several mental health and substance us...
Eligibility Criteria
Inclusion
- Adult, age 25-65
- DSM-5 CUD, moderate or higher (4+ DSM-5 symptoms)
- 4 or more days of cannabis use per week
- Reports inhalation as one route of administration
- Treatment-seeking (i.e., self-reported readiness to change of 5 or greater on a 0-10 readiness ruler)
- Stable domicile and reliable transportation, and willingness to attend in-person visits at SJHH Hamilton.
Exclusion
- Current psychotic symptoms, history of schizophrenia-spectrum disorders or bipolar disorder, or current PTSD
- Active suicidality (past 3 months) or history of severe suicidality (i.e., requiring hospitalization)
- Any other mental health condition deemed incompatible by the team
- High risk alcohol involvement and/or 4+ symptoms of alcohol use disorder
- Unstable management of an existing mental health condition or anticipation of a change to the treatment over the next 3 months
- Current unstable medical condition (e.g., diabetes)
- rTMS Contraindications: intracranial or metal implants in the head or nearby regions that cannot be safely removed; history of epilepsy or seizures; pregnancy (female participants only); pacemaker and/or implantable cardioverter-defibrillators).
- Medication contraindications (e.g., bupropion \>300 mg/day due to risk of seizures, benzodiazepine equivalent dose to lorazepam \>2 mg/day).
- History of recurrent headache or migraine (past year)
- Significant literacy, visual, or hearing problems
- Co-enrollment in a clinical drug trial
Key Trial Info
Start Date :
March 26 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06114212
Start Date
March 26 2024
End Date
December 1 2025
Last Update
January 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada, L8N 3K7